Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00768729 · ClinicalTrials.gov registry record · Phase 1
Safety of Immunosuppression Minimization in Children and Adolescents After Kidney Transplantation
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT00768729 is a Phase 1 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 7 participants.
The verdict
NCT00768729, a Phase 1 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
Kidney transplantation is widely considered to be the treatment of choice for children with End Stage Renal Disease (ESRD). The purpose of this study is to determine the safety of sirolimus monotherapy for long-term immunosuppression in children and adolescents after kidney transplantation.
Interventions
- DRUG Sirolimus
- DRUG MMF or Azathioprine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2009-05 |
| Est. Completion | 2012-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00768729
The ClinicalTrials.gov registry entry for NCT00768729 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sirolimus is the first listed.
NCT00768729 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00768729 about?
NCT00768729 is a clinical study titled "Safety of Immunosuppression Minimization in Children and Adolescents After Kidney Transplantation". Kidney transplantation is widely considered to be the treatment of choice for children with End Stage Renal Disease (ESRD). The purpose of this study is to determine the safety of sirolimus monotherapy for long-term immunosuppression in children and adolescents after kidney transplantation.
What is the current status of trial NCT00768729?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2009-05. Estimated completion is 2012-12.
What interventions are being tested in trial NCT00768729?
The interventions under investigation include: Sirolimus (DRUG), MMF or Azathioprine (DRUG).
Who is sponsoring clinical trial NCT00768729?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.